VistaGen: Is this relevant to us?18 Dec 2020 12:00
Newbie Alert: Hold your Fire...!
DECEMBER 18, 2020
VistaGen Therapeutics, Inc. [...] “today announced the pricing of its underwritten public offering consisting of 63,000,000 shares.....”
“Gross proceeds from the offering, before underwriting discounts and commissions and estimated offering expenses, are expected to be $100 million. All of the securities in the offering are being sold by VistaGen.”
“VistaGen intends to use the net proceeds from the offering for research, development and manufacturing and regulatory expenses associated with continuing development of PH94B, PH10, AV-101, and potential drug candidates to expand its CNS pipeline and for other working capital and general corporate purposes.”